Home › Agent Hub › Agent Tools › Part D coverage by drug › Glyxambi
Agent Tools
Glyxambi is a brand of empagliflozin / linagliptin. What agents check before quoting it: how many 2027 Part D plans cover it, on which tier, with what restrictions and copays, by plan type, carrier and state.
In 2027, 3,844 of 5,492 Medicare Part D and Medicare Advantage drug plans (70%) list Glyxambi on their formulary, across 219 of 286 formularies. The most common placement is tier 3 (3,548 plans, 92.3% of those covering it). 7 of the covering plans require prior authorization (0.2%), 0 step therapy and 3,805 a quantity limit.
451 covering plans charge a flat copay for a 30-day supply at a preferred retail pharmacy after the deductible — median $42, 86 of them $0; 3,393 charge coinsurance instead — median 22% of the drug's cost. Once a member's out-of-pocket drug spending reaches $2,400 in 2027, covered drugs cost $0 for the rest of the year.
2026: 4,806 of 5,496 plans covered it (87.4%); 2027: 3,844 of 5,492 (70%).
Of 4,367 plans offered in both years, 5 added it to the formulary and 909 dropped it.
Among plans covering it both years, 32 moved it to a higher tier and 269 to a lower one; 0 added prior authorization and 0 removed it.
| Tier | Plans |
|---|---|
| Tier 1 | 74 |
| Tier 2 | 207 |
| Tier 3 | 3,548 |
| Tier 4 | 7 |
| Tier 6 | 8 |
| Plan type | Plans covering | Share | Prior auth |
|---|---|---|---|
| Stand-alone Part D (PDP) | 77 of 323 | 23.8% | 0% |
| Medicare Advantage with drugs (MA-PD) | 2,243 of 3,200 | 70.1% | 0% |
| Special needs plans (SNP) | 1,524 of 1,969 | 77.4% | 0.5% |
| Carrier | Plans covering | Usual tier | Prior auth |
|---|---|---|---|
| Humana | 0 of 846 | No tier listed | 0 |
| UnitedHealthcare | 796 of 830 | Tier 3 | 0 |
| Devoted Health | 728 of 728 | Tier 3 | 0 |
| Aetna Medicare | 631 of 631 | Tier 3 | 0 |
| Wellcare | 200 of 268 | Tier 2 | 0 |
| HealthSpring | 0 of 226 | No tier listed | 0 |
| Kaiser Permanente | 0 of 112 | No tier listed | 0 |
| SCAN Health Plan | 83 of 83 | Tier 3 | 0 |
| Highmark Blue Cross Blue Shield or Highmark Blue Shield | 80 of 80 | Tier 3 | 0 |
| Alignment Health Plan | 77 of 77 | Tier 3 | 0 |
| Anthem Blue Cross and Blue Shield | 74 of 74 | Tier 3 | 0 |
| Wellpoint | 58 of 63 | Tier 3 | 0 |
| Priority Health Medicare | 0 of 40 | No tier listed | 0 |
| CarePlus Health Plans, Inc. | 0 of 37 | No tier listed | 0 |
| Zing Health | 36 of 36 | Tier 3 | 0 |
| Capital Blue Cross | 35 of 35 | Tier 3 | 0 |
| Prominence Health Plan | 29 of 29 | Tier 3 | 0 |
| Medica | 1 of 27 | Tier 3 | 0 |
| Anthem HealthKeepers | 22 of 26 | Tier 3 | 0 |
| Blue Cross Blue Shield of Michigan | 0 of 26 | No tier listed | 0 |
| State | Plans covering | Share |
|---|---|---|
| Alabama | 71 of 114 | 62.3% |
| Alaska | 2 of 9 | 22.2% |
| American Samoa | 1 of 1 | 100% |
| Arizona | 116 of 147 | 78.9% |
| Arkansas | 52 of 85 | 61.2% |
| California | 309 of 397 | 77.8% |
| Colorado | 61 of 106 | 57.5% |
| Connecticut | 43 of 54 | 79.6% |
| Delaware | 29 of 43 | 67.4% |
| District of Columbia | 8 of 12 | 66.7% |
| Florida | 371 of 545 | 68.1% |
| Georgia | 78 of 149 | 52.3% |
| Guam | 1 of 1 | 100% |
| Hawaii | 32 of 50 | 64% |
| Idaho | 29 of 45 | 64.4% |
| Illinois | 92 of 132 | 69.7% |
| Indiana | 102 of 138 | 73.9% |
| Iowa | 47 of 64 | 73.4% |
| Kansas | 59 of 84 | 70.2% |
| Kentucky | 71 of 121 | 58.7% |
| Louisiana | 82 of 125 | 65.6% |
| Maine | 33 of 52 | 63.5% |
| Maryland | 23 of 49 | 46.9% |
| Massachusetts | 72 of 89 | 80.9% |
| Michigan | 65 of 182 | 35.7% |
| Minnesota | 43 of 63 | 68.3% |
| Mississippi | 64 of 104 | 61.5% |
| Missouri | 123 of 170 | 72.4% |
| Montana | 6 of 27 | 22.2% |
| Nebraska | 36 of 51 | 70.6% |
| Nevada | 72 of 100 | 72% |
| New Hampshire | 12 of 25 | 48% |
| New Jersey | 53 of 73 | 72.6% |
| New Mexico | 45 of 68 | 66.2% |
| New York | 192 of 215 | 89.3% |
| North Carolina | 123 of 176 | 69.9% |
| North Dakota | 13 of 26 | 50% |
| Northern Mariana Islands | 1 of 1 | 100% |
| Ohio | 117 of 171 | 68.4% |
| Oklahoma | 44 of 81 | 54.3% |
| Oregon | 67 of 92 | 72.8% |
| Pennsylvania | 275 of 323 | 85.1% |
| Puerto Rico | 62 of 64 | 96.9% |
| Rhode Island | 22 of 29 | 75.9% |
| South Carolina | 49 of 89 | 55.1% |
| South Dakota | 15 of 30 | 50% |
| Tennessee | 109 of 156 | 69.9% |
| Texas | 288 of 407 | 70.8% |
| U.S. Virgin Islands | 1 of 1 | 100% |
| Utah | 33 of 53 | 62.3% |
| Vermont | 3 of 14 | 21.4% |
| Virginia | 79 of 144 | 54.9% |
| Washington | 68 of 114 | 59.6% |
| West Virginia | 38 of 69 | 55.1% |
| Wisconsin | 64 of 96 | 66.7% |
| Wyoming | 2 of 13 | 15.4% |
Medicare Part D paid for 243,834 30-day fills of Glyxambi in 2024 for about 28,712 enrollees, at an average total cost of $577.45 per 30-day fill (CMS Part D Prescribers by Geography and Drug, national).
Price Glyxambi and the rest of a client's list on every plan in their county.
Estimate Glyxambi costs by plan
Free tools for licensed insurance agents. Data from CMS public files; verify with plan documents before advising a client.
Counts are over every Medicare Advantage drug plan and stand-alone Part D plan in the CMS monthly formulary files, excluding employer plans. A plan counts as covering a drug when any strength or form of it is on the plan’s formulary; the tier, prior authorization, step therapy and quantity limit shown are the most favorable version on that formulary. Copays are for a 30-day supply at a preferred retail pharmacy after the deductible. This is a reference for licensed agents, not a plan recommendation; verify with the plan’s formulary before advising a client. Source: CMS Part D formulary files (release 10/08/2026). CMS formulary data.